ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2010
The highly virulent variola and monkeypox viruses express secreted inhibitors of type I interferon.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 65 citations in OpenAlex.
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- MGF110-2L deletion prevents IFN-I and inflammatory response, resulting in partial attenuation and protection against virulent ASFV.Journal of virology · 2026Article
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- Opposite regulation of immune genes in blood and skin highlights tissue-specific dynamics of mpox virus.Scientific reports · 2025Article
- Mpox 2022 to 2025 Update: A Comprehensive Review on Its Complications, Transmission, Diagnosis, and Treatment.Viruses · 2025Review
- Monkeypox Virus Subverts the Inflammatory Response of Macrophages at the Maternal-Fetal Interface.Journal of medical virology · 2025Article
- Advancing the understanding and management of Mpox: insights into epidemiology, disease pathways, prevention, and therapeutic strategies.BMC infectious diseases · 2025Review
- Monoclonal Antibodies in Light of Mpox Outbreak: Current Research, Therapeutic Targets, and Animal Models.Antibodies (Basel, Switzerland) · 2025Review
- Antigen recognition and immune response to monkeypox virus infection: implications for Mpox vaccine design - a narrative review.Le infezioni in medicina · 2025Review
- Mpox Virus and its ocular surface manifestations.The ocular surface · 2024Review
- A comprehensive review of monkeypox virus and mpox characteristics.Frontiers in cellular and infection microbiology · 2024Review
- Monkeypox Virus (MPXV) Infection: A Review.Infectious disorders drug targets · 2024Review
- Monkeypox: A comprehensive review of a multifaceted virus.Infectious medicine · 2023Review
- RELA tunes innate-like interferon I/III responses in human T cells.The Journal of experimental medicine · 2023Article
- Review
- Recent Advances in Research and Management of Human Monkeypox Virus: An Emerging Global Health Threat.Viruses · 2023Review
- Emergence, phylogeography, and adaptive evolution of mpox virus.New microbes and new infections · 2023Article
- Review
- The prospective outcome of the monkeypox outbreak in 2022 and characterization of monkeypox disease immunobiology.Frontiers in cellular and infection microbiology · 2023Article
- The evolving epidemiology of monkeypox virus.Cytokine & growth factor reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Variola virus (VARV) caused smallpox, one of the most devastating human diseases and the first to be eradicated, but its deliberate release represents a dangerous threat. Virulent orthopoxviruses infecting humans, such as monkeypox virus (MPXV), could fill the niche left by smallpox eradication and the cessation of vaccination. However, immunomodulatory activities and virulence determinants of VARV and MPXV remain largely unexplored. We report the molecular characterization of the VARV- and MPXV-secreted type I interferon-binding proteins, which interact with the cell surface after secretion and prevent type I interferon responses. The proteins expressed in the baculovirus system have been purified, and their interferon-binding properties characterized by surface plasmon resonance. The ability of these proteins to inhibit a broad range of interferons was investigated to identify potential adaptation to the human immune system. Furthermore, we demonstrate by Western blot and activity assays the expression of the type I interferon inhibitor during VARV and MPXV infections. These findings are relevant for the design of new vaccines and therapeutics to smallpox and emergent virulent orthopoxviruses because the type I interferon-binding protein is a major virulence factor in animal models, vaccination with this protein induces protective immunity, and its neutralization prevents disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.